P I Industries Ltd Q1 FY2026 Concall Summary

Key Takeaways

• Q1 on plan, H2-weighted: AgChem exports declined as customers balanced inventory, but new products commercialized in the last three years grew 46% YoY, and management expects supply acceleration in H2.
• Pharma breakout quarter: Revenue grew 186% YoY, driven by deepening relationships with biotech and big pharma innovators; two large pharma clients already onboarded, with two more expected by year-end.
• India's first discovery filed: Registration filed for PIOXANILIPROLE, a novel insecticide in the large Lepidopteran segment; commercialization expected in roughly two and a half years.
• Biologicals hit by regulatory disruption: Sales stopped on ~20% of domestic revenue due to abrupt regulatory challenges; management expects resolution in "maybe a month or so" but normalization will take time.
• What to watch next quarter: Whether biological regulatory issues resolve and sales resume, the pace of new pharma client onboarding, and any tariff developments on key export products.

Pharma: The Inflection Quarter

• 186% YoY growth driven by both product supply and the CRDMO services business; management is building a pipeline of late-stage DMO programs.
• Client acquisition on track: Two large pharma clients already onboarded against a goal of 3-4 for the year; trends indicate two more by year-end.
• Break-even in sight: Management targets a break-even EBITDA situation in the pharma business on a 12-to-18-month horizon.
• Revenue ambition: Looking to grow pharma revenue at least 2-3x over the next 3-4 years.
• CSM expertise as the bridge: PI's decades of experience making molecules efficiently for crop protection translates directly into pharma, where the core skill is the same: making the molecule in the most elegant, efficient, and cost-effective manner.

Dr. Ramesh S: "The way we look at things is that we focus on making the molecule. The molecule can impact plant health, or it can impact animal health, or it can impact human health. But the focus of PI as a whole is to make the molecule the most elegant, efficient, and cost effective manner."

AgChem Exports: Transitional Softness, H2 Recovery Expected

• CSM volume declined 9% in Q1, driven entirely by customer delivery schedules and inventory balancing; supplies are expected to renew in the second half.
• New products as the growth engine: Molecules commercialized in the last three years registered 46% YoY growth; 8-10 new molecules to be launched in FY26, with 6-7 commercialized in the remaining quarters.
• Long-term pipeline confidence: Development pipelines comprise 20+ new products in various phases of development and regulatory registration; a couple of newly commercialized molecules expected to provide substantial balancing contribution in the next 3-4 years.
• Tariff risk appears contained for now: On a key product in the US, management stated tariffs are "at present not applicable and we do not see any challenges," but did not address whether the customer would absorb tariffs if they become applicable.

Biologicals: Regulatory Disruption Masks Strategic Build

• Sales stopped on ~20% of domestic revenue due to abrupt regulatory challenges in the biological space; the acquired Plant Health Care business contributed \$3-4 million in the quarter and is performing in line with plan.
• Resolution expected soon, normalization later: Industry expects the regulatory issue to resolve in "maybe a month or so," but management cautioned that full normalization of sales "is going to take some time."
• Strategic logic intact: Biologicals carry a better margin profile than chemicals over the long term, and the government's policy agenda prioritizes biologicals; PI has used the disruption period to transform Jivagro's portfolio from generic products to specialty products suited for horticulture crops.
• Global scale-up underway: The Plant Health Care acquisition brings proprietary technologies including PREtec and Harpin; Jagresh Rana appointed as Global CEO of Biologicals.

Mayank Singhal: "Biological is the key agenda of the Government of India to create balanced, equitable environment for agriculture, and also one of Prime Minister's key agenda, and which also gave the Company the spirit to say we should invest in Biologicals. So, I am pretty sure this will be a top priority to resolve at every level."

PIOXANILIPROLE: India's First Discovery Filed

• Registration filed in India for a novel insecticide in the Lepidopteran space, a segment that addresses an insecticide market of a couple of thousand crore across multiple crops.
• Commercialization timeline: Product expected to come to life in roughly a two-and-a-half-year scenario; management declined to disclose development costs or further expenditure required for scale-up.
• Significance beyond size: Management frames the filing as validation of PI's decade-long innovation journey, with the ability to put proprietary innovation out into the market mattering more than the immediate revenue opportunity.

Mayank Singhal: "I am pleased to share, we have filed the registration of India's first discovery, PIOXANILIPROLE, a significant breakthrough of the innovation journey taken by PI over a decade ago, is now showing its early shoots."

Margins & Financials

• Gross margin expanded to 57.4% in Q1, driven by favorable product mix and cost optimization projects; management declined to raise the guided range of 50-52%, citing quarter-to-quarter mix variability.
• Pharma margin reclassification: Last year's pharma gross margin was reported at 42% but on a like-for-like basis was 52%, versus 55% this year, reflecting the higher development spend currently running through the pharma P&L.
• Trade receivables increased from the export segment in line with plan; domestic collections were slowed by fertilizer shortages that diverted farmer spending toward securing fertilizers.
• CAPEX of ₹700-800 crore planned for the year; one new plant expected to start by Q4 FY26, the other by Q1 or Q2 FY27.
• ETR guidance maintained at 22-23% for the next 2-3 years.

Domestic Business & Emerging Engines

• Domestic business grew 6% but could have been higher absent the biological regulatory disruption and fertilizer shortfalls that impacted Kharif season momentum; favorable monsoons and positive sowing trends provide a supportive backdrop.
• Electronic chemicals gaining traction: 5-7 products already developed, with approximately 10 projects being worked on actively with global customers; management expects this to become a meaningful segment in 4-5 years.
• Inorganic opportunities being evaluated across various business segments; business process reengineering underway including S4 HANA implementation and global supply chain integration.

Guidance & Commitments

Key Metrics